EGFR and non-small cell lung carcinoma: Lastly, a previously described mechanism for activation of the EGFR-RAS-MEK pathway is the somatic mutation of a RAS gene, BRAF, or EGFR, which can be relatively frequent events in non-small cell lung carcinomas.